To the Stakeholders of GSK plc:

**Bureau Veritas’ Independent Assurance Statement**

Bureau Veritas UK Ltd has been engaged by GSK to provide independent assurance of its Environment, Health and Safety (EHS) performance data for 2015. The objective of Bureau Veritas’ work is to express an opinion on the accuracy and reliability of the EHS data and to provide a summary of our findings. The EHS data have been prepared by GSK plc.

**Scope of the Assurance**

- the data addresses energy consumption/generation, CO2 emissions, water consumption, wastewater discharge, solid waste, and health and safety indicators.

The assurance focused on data management processes and the EHS data at sites have been verified to a reasonable level of assurance and the rest of the work was carried out to provide a limited level of assurance.

**Methodology**

Assessment of EHS data and associated data management processes, including:

- detailed review of the integrity of selected datasets and data aggregation and checking processes at a corporate level. This included checking of conversion factors, mass balance calculations and other equations used in data calculations;
- visits to five GSK sites where EHS data management was assessed and data was sampled back to source where possible. The sites were chosen to represent manufacturing facilities with significant environmental impact, GSK operations and geographical spread: Cork (Ireland), Dungarvan (Ireland), Karachi (Pakistan), Saint Foy (Canada) and Ware (United Kingdom);
- interviews with senior EHS staff across the business to understand GSK’s evolving approach to data management.

**Limitations and Standards**

A limited level of assurance was undertaken taking into account the requirements of the International Standard on Assurance Engagements 3000 – Assurance Engagements other than Audits or Reviews of Historical Financial Information (‘ISAE 3000’) and, concerning CO2 emissions, the requirements of the International Standard on Assurance Engagements 3410 - Assurance Engagements on Greenhouse Gas Statements (‘ISAE 3410’), incorporated to Bureau Veritas internal protocol for the assurance of sustainability reports.

This statement should not be relied upon to detect all errors, omissions or misstatements.

The following exclusions apply:

- text associated with the EHS performance and included in GSK’s corporate responsibility reporting;
- activities outside the defined reporting period.

**Opinion and Recommendations**

Based on the assurance work we carried out and the evidence we were presented with, as per the scope of work, nothing came to our attention to suggest that factual information, performance metrics and data contained within the GSK’s 2015 EHS performance data do not:

- provides a fair summary of EHS-related activities and performance;
- contain performance metrics and information that are based on established collection and collation processes, and are deemed to be free from significant error, omission or bias.

The quality of data evidenced at site and consolidated level was seen to be based on an up to date and recently implemented data management system (EHS Central) and supporting processes and guidance.

Any data corrections identified by Bureau Veritas were willingly applied by GSK prior to publication, or qualified in
Observations of good practice

- The recently implemented EHS Central system is tailored to the GSK business, providing a robust and functional solution for the collection and management of EHS data;
- Its implementation has been comprehensive across GSK’s manufacturing, research and commercial operations, with associated training to individuals with data entry and review responsibilities;
- The list of KPIs for reporting has been revised and should result in better understanding and interpretation of what is required at site level, as well as continued meaningful disclosure at the corporate level;
- GSK personnel were open and transparent at all stages of the verification process and receptive to suggestions for change and improvements;
- The EHS is supporting the integration of sustainability across GSK Global Manufacture and Supply (GMS);
- The identification of site level anomalies or errors, and use of change logs continue to strengthen EHS accuracy, comparability and timeliness of data collection;
- The accident reporting system is now managed through EHS Central and is being integrated into employee targets (non-financial), Intended to create a culture of near miss reporting (NIR);
- GSK personnel were open and transparent at all stages of the verification process and receptive to suggestions for change and improvements.

Recommendations

There are a number of areas that could lead to further refinement, some of which are included below:

- GSK should review comments to the EHS system such as change control notes and system notes;
- GSK should review emission factors, their source, and Standard Operating procedures to ensure quality transparent reporting of global air travel;
- GSK should review and develop procedures to ensure consistency with existing data management under the responsibility of GMS;
- GSK should consider the timing of information provided to reviewers prior to site visits to prevent data gaps;

A fuller management report is developed and provided to GSK with more detailed findings and recommendations for future data reporting; individual site reports are also provided to feedback more fully on the site visits.

Statement of independence, impartiality and competence

Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 185 years of history. The assurance team for this work has extensive experience in environmental, social, ethical and health and safety information, systems and processes and does not have any involvement in any other Bureau Veritas projects with GSK. Bureau Veritas has implemented a Code of Ethics across the business to ensure that its staff members avoid conflict of interest and maintain high ethical standards in their day-to-day business activities.

London, February 2016